Your browser is no longer supported. Please, upgrade your browser.
Incyte Corporation
IndexS&P 500 P/E29.14 EPS (ttm)2.42 Insider Own0.70% Shs Outstand220.84M Perf Week9.08%
Market Cap15.69B Forward P/E16.08 EPS next Y4.38 Insider Trans-2.35% Shs Float217.58M Perf Month7.04%
Income534.60M PEG1.39 EPS next Q1.01 Inst Own93.80% Short Float2.52% Perf Quarter-7.47%
Sales2.91B P/S5.39 EPS this Y-166.00% Inst Trans-0.63% Short Ratio3.00 Perf Half Y-15.10%
Book/sh14.26 P/B4.93 EPS next Y24.92% ROA14.00% Target Price93.12 Perf Year-15.47%
Cash/sh10.24 P/C6.87 EPS next 5Y20.89% ROE18.70% 52W Range61.91 - 101.47 Perf YTD-19.10%
Dividend- P/FCF28.87 EPS past 5Y33.32% ROI-12.40% 52W High-30.65% Beta0.72
Dividend %- Quick Ratio3.90 Sales past 5Y28.80% Gross Margin95.80% 52W Low13.67% ATR2.14
Employees1773 Current Ratio3.90 Sales Q/Q31.00% Oper. Margin21.90% RSI (14)63.48 Volatility3.60% 3.22%
OptionableYes Debt/Eq0.01 EPS Q/Q-48.50% Profit Margin18.40% Rel Volume1.96 Prev Close70.37
ShortableYes LT Debt/Eq0.01 EarningsNov 02 BMO Payout0.00% Avg Volume1.83M Price70.37
Recom2.20 SMA206.43% SMA505.40% SMA200-8.45% Volume0 Change0.00%
Nov-19-21Initiated BMO Capital Markets Market Perform $75
Jul-20-21Upgrade The Benchmark Company Hold → Buy $89
Feb-10-21Downgrade SVB Leerink Mkt Perform → Underperform $70
Jan-07-21Initiated Truist Buy $120
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
Nov-09-21 08:30AM  
Nov-04-21 10:07AM  
Nov-02-21 12:00PM  
Nov-01-21 09:16AM  
Oct-29-21 09:48AM  
Oct-28-21 10:33AM  
Oct-27-21 10:14AM  
Oct-26-21 03:02PM  
Oct-22-21 09:26AM  
Oct-21-21 06:40AM  
Oct-20-21 01:23PM  
Oct-13-21 10:29AM  
Oct-12-21 10:57AM  
Oct-02-21 05:15AM  
Sep-30-21 05:56AM  
Sep-29-21 10:47AM  
Sep-28-21 05:00PM  
Sep-27-21 09:23AM  
Sep-23-21 11:08AM  
Sep-22-21 01:54PM  
Sep-21-21 04:13PM  
Sep-20-21 01:46PM  
Sep-17-21 04:00PM  
Sep-13-21 04:30PM  
Sep-02-21 11:31AM  
Sep-01-21 10:44AM  
Aug-27-21 11:09AM  
Aug-26-21 04:01PM  
Aug-24-21 08:30AM  
Aug-19-21 10:02AM  
Aug-17-21 08:28AM  
Aug-16-21 07:00PM  
Aug-10-21 02:49AM  
Aug-07-21 08:01AM  
Aug-03-21 04:30PM  
Aug-02-21 09:36AM  
Jul-31-21 08:38AM  
Jul-28-21 01:51PM  
Jul-27-21 03:03PM  
Jul-23-21 04:30PM  
Jul-22-21 11:40AM  
Jul-19-21 11:16AM  
Jul-16-21 01:57PM  
Jul-15-21 08:00AM  
Jul-14-21 05:00PM  
Jul-09-21 09:47AM  
Jul-06-21 12:43AM  
Jun-28-21 01:18PM  
Jun-25-21 07:42AM  
Jun-24-21 03:30PM  
Jun-20-21 05:11AM  
Jun-14-21 10:34AM  
Jun-12-21 05:01PM  
Jun-11-21 11:40AM  
Jun-09-21 04:00PM  
Jun-08-21 07:30AM  
Jun-04-21 02:00PM  
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dhanak DashyantEVP & Chief Scientific OfficerOct 01Sale68.6738926,71331,263Oct 04 04:41 PM
Pasquale Maria EEVP & General CounselSep 24Option Exercise65.3638224,96836,187Sep 28 08:18 AM
SWAIN PAULA JEVP, Human ResourcesSep 20Option Exercise73.211,35699,27360,959Sep 21 04:09 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 01Sale76.7138829,76331,652Sep 03 07:40 AM
Dhanak DashyantEVP & Chief Scientific OfficerAug 02Sale77.4938930,14432,040Aug 04 04:16 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 29Sale78.294,911384,48227,005Aug 02 04:14 PM
Wenqing YaoEVP, Head of Discovery ChemJun 29Sale85.3727,1942,321,55294,080Jun 30 04:11 PM
Pasquale Maria EEVP & General CounselJun 18Option Exercise65.3625516,66730,193Jun 22 04:04 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 10Option Exercise65.423,845251,54030,390Jun 14 04:28 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 10Sale87.003,845334,51526,545Jun 14 04:28 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 01Sale84.1339533,23126,545Jun 03 04:42 PM
BAKER BROS. ADVISORS LPDirectorMay 14Option Exercise18.9740,000758,80029,334,516May 18 04:25 PM
Pasquale Maria EEVP & General CounselApr 23Option Exercise65.361278,30129,938Apr 27 04:57 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 01Sale81.5739632,30227,336Apr 05 04:25 PM
Morrissey Michael JamesEVP, Head of Tech. OperationsMar 29Sale81.0820,0001,621,60045,452Mar 31 04:10 PM
Pasquale Maria EEVP & General CounselMar 12Option Exercise65.361288,36630,328Mar 16 04:17 PM
Dhanak DashyantEVP & Chief Scientific OfficerMar 01Sale79.7339531,49327,732Mar 03 04:28 PM
Hoppenot HerveChairman / CEOFeb 23Buy77.3712,9251,000,007284,231Feb 23 04:54 PM
Pasquale Maria EEVP & General CounselFeb 16Option Exercise65.361278,30130,200Feb 18 04:38 PM
Dhanak DashyantEVP & Chief Scientific OfficerFeb 01Option Exercise65.4296162,86929,483Feb 03 04:27 PM
Dhanak DashyantEVP & Chief Scientific OfficerFeb 01Sale90.001,356122,04028,127Feb 03 04:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 25Option Exercise72.864,116299,89231,274Jan 27 05:03 PM
Stein Steven HEVP & Chief Medical OfficerJan 25Option Exercise68.623,795260,413123,539Jan 27 05:09 PM
Wenqing YaoEVP, Head of Discovery ChemJan 25Option Exercise73.2121,5451,577,309163,770Jan 27 05:32 PM
Wenqing YaoEVP, Head of Discovery ChemJan 25Sale100.0021,5452,154,500143,784Jan 27 05:32 PM
Stein Steven HEVP & Chief Medical OfficerJan 25Sale100.003,795379,500119,744Jan 27 05:09 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 25Sale99.005,116506,48426,158Jan 27 05:03 PM
Flannelly Barry PEVP & General Manager USJan 25Sale100.002,744274,40049,994Jan 27 04:52 PM
Pasquale Maria EEVP & General CounselJan 11Option Exercise65.361278,30130,073Jan 13 04:15 PM
Pasquale Maria EEVP & General CounselDec 11Option Exercise65.361288,36629,946Dec 15 04:51 PM